About US
Contact us
-
US FDA fast tracks Inotrem’s nangibotide for septic shockThe US Food and Drug Administration (FDA) has awarded fast track designation to French biotechnology firm Inotrem’s nangibotide programme, which is being developed to treat septic shock. Nangibotide2019/9/4
-
Insilico Medicine develops new AI drug discovery systemInsilico Medicine has developed an artificial intelligence (AI)-powered system to facilitate the creation of therapeutic molecules. The AI technology GENTRL is thought to speed up the drug discovery2019/9/4
-
Sandoz licences proposed multiple sclerosis biosimilar from PolpharmaNovartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizuma2019/9/3
-
Novartis’s heart failure drug Entresto presents mixed trial resultsNovartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.2019/9/3
-
Gavi Vaccine Alliance seeks $7. 4bn to immunise 300 million peopleGavi, the Vaccine Alliance has initiated a $7.4bn fundraising drive to support the immunisation of 300 million children against 18 diseases, which could save up to eight million lives from 2021-25. D2019/9/2
-
Researchers find new drug with promise for malaria treatmentAn international research team led by the University of Glasgow has discovered a new drug that could kill the malaria-causing parasite, offering hope for the treatment of the disease. The drug stops2019/9/2
-
Study finds menopausal HRT drastically increases breast cancer riskResearch published in the Lancet has found that women taking hormone replacement therapy (HRT) to mitigate the symptoms of menopause for longer than a year have a significantly higher risk of breast2019/8/30
-
SpringWorks receives breakthrough status for desmoid tumour drugSpringWorks Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for nirogacestat, an oral inhibitor for treating desmoid tumours or deep fibromat2019/8/30
-
ADCendo secures loan to advance ADCs for cancer treatmentADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers. The company secured the $1.48m convertible loan as part of the BioInn2019/8/29
-
AstraZeneca’s SLE drug performs well in Phase III trialAstraZeneca has announced anifrolumab met the primary endpoint of the Phase III Tulip trial studying 373 systemic lupus erythematosus (SLE) patients. The primary endpoint for the trial was reduction2019/8/29